Results from the study show the DISCERN Alzheimer's disease diagnostic test can save nearly $5 million in just three years for a Medicare Advantage plan with 1 million beneficiaries.
New data suggests that over half of symptomatic Alzheimer's patients are misdiagnosed for the disease in the primary care setting.
A recent study revealed that low levels of ergothioneine in blood plasma may predict an increased risk of cognitive impairment and dementia.
There’s no easy way to distinguish a primary tauopathy—a group of rare brain diseases—because the symptoms of each type are too similar.
Read More
Researchers identified a biomarker that can help physicians diagnose Alzheimer’s earlier, as patients transition to cognitive impairment.
Read More
The researchers identified and validated a new protein that is able to reduce neuronal firing and induce a loss of neurite integrity.
Read More
Researchers have evidence that higher levels of circulating cell-free genomic DNA in the blood may signal early signs of dementia.
Read More
Researchers created a method to detect build-up of amyloid β in the brain, a characteristic of Alzheimer’s, from biomarkers in blood samples.
Read More
Researchers designed in silico “molecular probes” able to track the progress of a protein that misbehaves in neurodegenerative diseases.
Read More
The two-year award will allow the company to screen data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Read More
This study developed a rapid assay method to quantitatively determine nervous system-derived EVs in plasma using nano-flow cytometry tech.
Read More
It is well established that APOE4, a variant of the apolipoprotein E gene, carries a strong risk for Alzheimer’s disease.
Read More
Research shows how large-scale, sensor-based health monitoring can address age-related diseases and health problems that are discovered late.
Read More
A new study identified multiple new risk genes for Alzheimer’s disease and a rare, related brain disorder through new testing methods.
Read More
The FDA granted Roche Breakthrough Device Designation for its Elecsys Amyloid Plasma Panel, designed to enable earlier Alzheimer’s detection.
Read More
A new, free, online, clinician-administered tool could greatly increase the likelihood of early of primary progressive aphasia detection.
Read More
Many neurodegenerative diseases, like Alzheimer’s, have been attributed to misfolding of proteins and peptides.
Read More
An immuno-infrared sensor can identify signs of Alzheimer’s in the blood up to 17 years before the first clinical symptoms appear.
Read More